Assessment Status | Rapid Review complete |
HTA ID | 23045 |
Drug | Brexucabtagene Autoleucel |
Brand | Tecartus® |
Indication | Adults 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia |
Assessment Process | |
Rapid review commissioned | 24/07/2023 |
Rapid review completed | 10/08/2023 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brexucabtagene autoleucel compared with the current standard-of-care. |